Research suggests Pirtobrutinib may provide a ... - CLL Support
Research suggests Pirtobrutinib may provide a safe and manageable risk of bleeding in those requiring antithrombotic therapy
You need to be a member of this community to see this post.
Read more about...
- Warfarin
- Aspirin
- Ibrutinib
- Anticoagulants
- Blood Transfusion
- Apixaban
- Rivaroxaban
- Heparin
- Vascular conditions
- Edoxaban
- Fondaparinux
- Salicylic acid
- Acalabrutinib
3 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
BTK inhibitor challenges by Dr. Nicole Lamanna
Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges....
Related Posts
- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Ibrutinib, Acalabrutinib, or Zanubrutinib - Real-World Study Shows Limited Implementation of Reccomended Biomarker Testing in CLL
- FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
- BTK Degrader Shows Potential for Treating Refractory CLL and SLL
